2,6-Heptadienoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,6-Heptadienoic acid
• 英文别名: hepta-2,6-dienoic acid
• 化学式: C₇H₁₀O₂
• 分子量: 126.15
• InChiKey: QQVKNEQDEIZBLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  tert-butyl (E)-hepta-2,6-dienoate 、 三氟乙酸 在 crude product 、 ethyl acetate n-hexane 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以afforded 2,6-heptadienoic acid 6 (1.67 g, 68%) as a colorless oil的产率得到2,6-Heptadienoic acid
  参考文献：
  名称：

  Migrastatin analog compositions and uses thereof

  摘要：

  在一个方面，本发明提供了药物组合物，包括通式（I）的化合物的治疗有效量，其中R1-R6，Ra-Rc，Q，Y1，Y2和n如本文所定义，该组合物配制用于给予受试者剂量为体重约0.1毫克/千克至约50毫克/千克之间的治疗。在另一个方面，本发明提供了一种治疗乳腺肿瘤转移的方法，包括向需要治疗的受试者直接给予上述创新组合物的治疗有效量和药学上可接受的载体、辅料或载体。

  公开号：

  US08202911B2

文献信息

• Halogen substituted metallocene compounds for olefin polymerization
  申请人：Voskoboynikov Z. Alexander

  公开号：US20070135594A1

  公开（公告）日：2007-06-14

  A metallocene compound is represented by the formula (1): AMX n-1 wherein M is a transition metal atom having a coordination number of n selected from Group 3, 4, 5 or 6 of the Periodic Table of Elements, or a lanthanide metal atom, or actinide metal atom; A is a substituted monocyclic or polycyclic arenyl ligand pi-bonded to M, wherein said arenyl ligand includes at least one halogen substituent directly bonded to any sp 2 carbon atom at a bondable ring position of the ligand; and the or each X is a univalent anionic ligand, or two X are joined and bound to the metal atom to form a metallocycle ring, or two X are joined to form a chelating ligand, a diene ligand, or an alkylidene ligand.

  一种金属烯化合物可以用公式(1)表示： AMX n-1 其中，M是具有配位数n的过渡金属原子，选自元素周期表第3、4、5或6族，或为镧系金属原子，或锕系金属原子；A是与M以π键结合的取代的单环或多元环芳基配体，其中所述芳基配体包括至少一个直接键合到配体的可键合环位上的任意sp2碳原子上的卤素取代基；而X是单价阴离子配体，或者两个X连接并与金属原子结合形成一个金属环烯环，或者两个X连接形成一个螯合配体、二烯配体或烷基亚烯配体。
• [EN] MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS DE SUBSTANCES ANALOGUES A LA MIGRASTATINE ET LEURS UTILISATIONS
  申请人：CORNELL RES FOUNDATION INC

  公开号：WO2004087672A1

  公开（公告）日：2004-10-14

  In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R1-R6, Ra-RC, Q, Y1, Y2 and n are as defined herein, whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg to about 50 mg/kg of body weight. In another aspect, the present invention provides a method for treating breast tumor metastasis in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the inventive composition described directly above and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  在一方面，本发明提供了包含式(I)化合物的治疗有效量的药物组合物，其中R1-R6，Ra-RC，Q，Y1，Y2和n如本文所述定义，该组合物为用于向受试者给药而配制成，剂量为约0.1 mg/kg至约50 mg/kg体重。在另一方面，本发明提供了一种治疗受试者乳腺癌转移的方法，包括向需要治疗的受试者给药治疗有效量的上述创新组合物以及药用可接受载体、佐剂或车辆。
• Isomigrastatin Analogs In The Treatment Of Cancer
  申请人：Danishefsky Samuel J.

  公开号：US20090054488A1

  公开（公告）日：2009-02-26

  The present invention provides compounds having formula (I): (I) wherein n, R 1 -R 5 , R a -R b , Q, Y 1 and Y 2 are as defined herein; and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis.

  本发明提供具有以下式（I）的化合物：（I）其中n，R1-R5，Ra-Rb，Q，Y1和Y2如本文所定义；此外还提供了其合成方法、组合物以及在治疗包括癌症、转移和涉及增加血管生成的各种疾病中使用的方法。
• KINASE INHIBITORS
  申请人：PRINCIPIA BIOPHARMA, INC.

  公开号：US20140323464A1

  公开（公告）日：2014-10-30

  Provided herein are kinase inhibiting compounds and methods of using the same.

  提供的是激酶抑制化合物及其使用方法。
• [EN] TRANSITION METAL COMPOUNDS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION<br/>[FR] COMPOSES METALLIQUES DE TRANSITION POUR LA POLYMERISATION D'OLEFINES ET L'OLIGOMERISATION
  申请人：EXXONMOBIL CHEM PATENTS INC

  公开号：WO2005118605A1

  公开（公告）日：2005-12-15

  This invention relates to new transition metal catalyst compounds represented by the formula (I): where: M and M' are, independently, a group 8, 9, 10 or 11 transition metal, preferably Ni, Co, Pd, Cu or Fe; each R group is, independently, is, hydrogen, or a hydrocarbyl, substituted hydrocarbyl, halocarbyl, substituted halocarbyl, silylcarbyl, substituted silylcarbyl, germylcarbyl, or substituted germylcarbyl substituents, and optionally, adjacent R groups may join together to form a substituted or unsubstituted, saturated, partially unsaturated, or aromatic cyclic or polycyclic substituent; R' is hydrogen, or a hydrocarbyl, substituted hydrocarbyl, halocarbyl, substituted halocarbyl, silylcarbyl, substituted silylcarbyl, germylcarbyl, or substituted germylcarbyl substituents, and optionally, adjacent R groups may join together with R' to form a substituted or unsubstituted, saturated, partially unsaturated, or aromatic cyclic or polycyclic substituent; each X group is, independently, is, hydrogen, a halogen, or a hydrocarbyl, substituted hydrocarbyl, halocarbyl, substituted halocarbyl, silylcarbyl, substituted sililcarbyl, germylcarbyl, or substituted germylcarbyl substituents, and optionally, adjacent X groups may join together to form a substituted or unsubstituted, saturated, partially unsaturated, or aromatic cyclic or polycyclic substituent; m and m’ are, independently, 0, 1, 2, or 3; z and z’ are, independently, 0, 1, 2, or 3; N is nitrogen; Q is hydrogen, or a hydrocarbyl, substituted hydrocarbyl, halocarbyl, substituted halocarbyl, silylcarbyl, substituted silylcarbyl, germylcarbyl, or substituted germylcarbyl substituents; Q’ is hydrogen, or a hydrocarbyl, substituted hydrocarbyl, halocarbyl, substituted halocarbyl, silylcarbyl, substituted silylcarbyl, germylcarbyl or substituted germylcarbyl substituents; and L is a hydrocarbyl, substituted hydrocarbyl, halocarbyl, substituted halocarbyl, silylcarbyl, substituted silylcarbyl, germylcarbyl, or substituted germylcarbyl substituent.

  这项发明涉及由式(I)表示的新过渡金属催化剂化合物，其中：M和M'分别是8、9、10或11族过渡金属，优选为Ni、Co、Pd、Cu或Fe；每个R基分别是氢，或烃基，取代烃基，卤代烃基，取代卤代烃基，硅烃基，取代硅烃基，锗烃基，或取代锗烃基取代基，且可选地，相邻的R基可以结合在一起形成取代或未取代的饱和、部分不饱和或芳香环或多环取代基；R'是氢，或烃基，取代烃基，卤代烃基，取代卤代烃基，硅烃基，取代硅烃基，锗烃基，或取代锗烃基取代基，且可选地，相邻的R基可以与R'结合在一起形成取代或未取代的饱和、部分不饱和或芳香环或多环取代基；每个X基分别是氢，卤素，或烃基，取代烃基，卤代烃基，取代卤代烃基，硅烃基，取代硅烃基，锗烃基，或取代锗烃基取代基，且可选地，相邻的X基可以结合在一起形成取代或未取代的饱和、部分不饱和或芳香环或多环取代基；m和m'分别为0、1、2或3；z和z'分别为0、1、2或3；N为氮；Q为氢，或烃基，取代烃基，卤代烃基，取代卤代烃基，硅烃基，取代硅烃基，锗烃基，或取代锗烃基取代基；Q'为氢，或烃基，取代烃基，卤代烃基，取代卤代烃基，硅烃基，取代硅烃基，锗烃基，或取代锗烃基取代基；L为烃基，取代烃基，卤代烃基，取代卤代烃基，硅烃基，取代硅烃基，锗烃基，或取代锗烃基取代基。

表征谱图